-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
MiNK Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2025.
- MiNK Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$2.89M, a 59.8% decline year-over-year.
- MiNK Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$12.4M, a 10.3% increase year-over-year.
- MiNK Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$10.8M, a 52% increase from 2023.
- MiNK Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$22.5M, a 19.8% increase from 2022.
- MiNK Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$28M, a 7.35% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)